Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

LSTA Lisata Therapeutics Inc

Price (delayed)

$2.08

Market cap

$17.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.4

Enterprise value

$1.72M

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely ...

Highlights
The EPS has grown by 7% YoY and by 4.4% from the previous quarter
The net income has grown by 4.1% YoY and by 3.6% from the previous quarter
LSTA's equity is down by 39% YoY and by 12% from the previous quarter
Lisata Therapeutics's quick ratio has decreased by 25% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of LSTA
Market
Shares outstanding
8.62M
Market cap
$17.93M
Enterprise value
$1.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.59
Price to sales (P/S)
17.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.72
Earnings
Revenue
$1M
Gross profit
$1M
Operating income
-$22.41M
Net income
-$19.99M
EBIT
-$20.78M
EBITDA
-$20.61M
Free cash flow
-$19.36M
Per share
EPS
-$2.4
EPS diluted
-$2.4
Free cash flow per share
-$2.32
Book value per share
$3.52
Revenue per share
$0.12
TBVPS
$4.18
Balance sheet
Total assets
$35M
Total liabilities
$5.69M
Debt
$0
Equity
$29.57M
Working capital
$28.97M
Liquidity
Debt to equity
0
Current ratio
6.16
Quick ratio
5.73
Net debt/EBITDA
0.79
Margins
EBITDA margin
-2,060.9%
Gross margin
100%
Net margin
-1,998.5%
Operating margin
-2,240.9%
Efficiency
Return on assets
-48.7%
Return on equity
-55.3%
Return on invested capital
-145.3%
Return on capital employed
-70.7%
Return on sales
-2,078.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LSTA stock price

How has the Lisata Therapeutics stock price performed over time
Intraday
-12.42%
1 week
-13.69%
1 month
3.54%
1 year
-28.52%
YTD
-30.2%
QTD
-11.49%

Financial performance

How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$22.41M
Net income
-$19.99M
Gross margin
100%
Net margin
-1,998.5%
LSTA's operating income is up by 13% year-on-year and by 4.6% since the previous quarter
The net income has grown by 4.1% YoY and by 3.6% from the previous quarter

Price vs fundamentals

How does LSTA's price correlate with its fundamentals

Growth

What is Lisata Therapeutics's growth rate over time

Valuation

What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
0.59
P/S
17.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.72
The EPS has grown by 7% YoY and by 4.4% from the previous quarter
LSTA's equity is down by 39% YoY and by 12% from the previous quarter
LSTA's price to book (P/B) is 12% higher than its 5-year quarterly average of 0.6 but 4.3% lower than its last 4 quarters average of 0.7

Efficiency

How efficient is Lisata Therapeutics business performance
The return on invested capital has dropped by 76% year-on-year and by 17% since the previous quarter
LSTA's ROE is down by 46% YoY and by 9% from the previous quarter
Lisata Therapeutics's return on assets has decreased by 41% YoY and by 8% QoQ

Dividends

What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LSTA.

Financial health

How did Lisata Therapeutics financials performed over time
The company's total assets fell by 36% YoY and by 8% QoQ
Lisata Therapeutics's quick ratio has decreased by 25% YoY and by 25% from the previous quarter
The debt is 100% less than the equity
LSTA's equity is down by 39% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.